Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor,
R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment
of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.